Literature DB >> 25501318

Current status on histological classification in Cushing's disease.

Luis V Syro1, Fabio Rotondo, Michael D Cusimano, Antonio Di Ieva, Eva Horvath, Lina M Restrepo, Min Wong, Donald W Killinger, Harley Smyth, Kalman Kovacs.   

Abstract

INTRODUCTION: Managing Cushing's disease remains a challenge. Surgery is the first option of treatment and it offers a high success rate. Even in cases where biochemical remission is not achieved, it is crucial to obtain surgical tissue for morphological diagnosis because the therapeutic approach can be modified according to the findings.
MATERIALS AND METHODS: A literature search was performed using PubMed for information regarding pathology and Cushing's disease.
RESULTS: The histopathological features found in the pituitary gland of patients with Cushing's disease are presented.
CONCLUSION: Different subtypes of ACTH-producing pituitary tumors are recognized and characterized. The significance of finding a normal pituitary gland with or without Crooke's changes is also discussed.

Entities:  

Mesh:

Year:  2015        PMID: 25501318     DOI: 10.1007/s11102-014-0619-0

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  29 in total

Review 1.  Update in the medical therapy of Cushing's disease.

Authors:  Lynnette K Nieman
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2013-08       Impact factor: 3.243

Review 2.  Efficacy of medical treatment in Cushing's disease: a systematic review.

Authors:  Mônica R Gadelha; Leonardo Vieira Neto
Journal:  Clin Endocrinol (Oxf)       Date:  2013-11-12       Impact factor: 3.478

3.  O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas.

Authors:  Fateme Salehi; Bernd W Scheithauer; Kalman Kovacs; Eva Horvath; Luis V Syro; Soniya Sharma; Branavan Manoranjan; Michael Cusimano
Journal:  Neurosurgery       Date:  2012-02       Impact factor: 4.654

4.  SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases.

Authors:  H Bode; M Seiz; A Lammert; M A Brockmann; W Back; H-P Hammes; C Thomé
Journal:  Exp Clin Endocrinol Diabetes       Date:  2010-05-21       Impact factor: 2.949

Review 5.  Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies.

Authors:  Gerald Raverot; Emmanuel Jouanneau; Jacqueline Trouillas
Journal:  Eur J Endocrinol       Date:  2014-03-13       Impact factor: 6.664

6.  High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease.

Authors:  Akira Takeshita; Naoko Inoshita; Manabu Taguchi; Chikao Okuda; Noriaki Fukuhara; Kenichi Oyama; Kenichi Ohashi; Toshiaki Sano; Yasuhiro Takeuchi; Shozo Yamada
Journal:  Eur J Endocrinol       Date:  2009-07-09       Impact factor: 6.664

Review 7.  Aggressive pituitary adenomas--diagnosis and emerging treatments.

Authors:  Antonio Di Ieva; Fabio Rotondo; Luis V Syro; Michael D Cusimano; Kalman Kovacs
Journal:  Nat Rev Endocrinol       Date:  2014-05-13       Impact factor: 43.330

8.  MGMT expression and pituitary tumours: relationship to tumour biology.

Authors:  Ann McCormack; Warren Kaplan; Anthony J Gill; Nicholas Little; Raymond Cook; Bruce Robinson; Roderick Clifton-Bligh
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

Review 9.  Medical management of Cushing's disease: what is the future?

Authors:  Maria Fleseriu; Stephan Petersenn
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

Review 10.  New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy.

Authors:  Maria Fleseriu; Stephan Petersenn
Journal:  J Neurooncol       Date:  2013-05-15       Impact factor: 4.130

View more
  6 in total

1.  Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas.

Authors:  Sema Ciftci Dogansen; Gulsah Yenidunya Yalin; Seher Tanrikulu; Sakin Tekin; Nihan Nizam; Bilge Bilgic; Serra Sencer; Sema Yarman
Journal:  Pituitary       Date:  2018-08       Impact factor: 4.107

Review 2.  Clinical Impact of the Current WHO Classification of Pituitary Adenomas.

Authors:  W Saeger; J Honegger; M Theodoropoulou; U J Knappe; C Schöfl; S Petersenn; R Buslei
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

3.  Significance of Crooke's Hyaline Change in Nontumorous Corticotrophs of Patients With Cushing Disease.

Authors:  Amit Akirov; Vincent Larouche; Ilan Shimon; Sylvia L Asa; Ozgur Mete; Anna M Sawka; Fred Gentili; Shereen Ezzat
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-18       Impact factor: 5.555

4.  Sparsely Granulated Corticotroph Pituitary Macroadenoma Presenting With Pituitary Apoplexy Resulting in Remission of Hypercortisolism.

Authors:  Tao Liu; John P Rossiter; Robyn L Houlden; Sara Awad
Journal:  AACE Clin Case Rep       Date:  2022-04-08

5.  Clinicopathological predictive factors in the early remission of corticotroph pituitary macroadenomas in a tertiary referral centre.

Authors:  Przemysław Witek; Grzegorz Zieliński; Katarzyna Szamotulska; Maria Maksymowicz; Grzegorz Kamiński
Journal:  Eur J Endocrinol       Date:  2016-01-25       Impact factor: 6.664

6.  Increased expression of the microRNA 106b~25 cluster and its host gene MCM7 in corticotroph pituitary adenomas is associated with tumor invasion and Crooke's cell morphology.

Authors:  Filip Garbicz; Dawid Mehlich; Beata Rak; Emir Sajjad; Maria Maksymowicz; Wiktor Paskal; Grzegorz Zieliński; Paweł K Włodarski
Journal:  Pituitary       Date:  2017-08       Impact factor: 4.107

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.